Simponi approved for non-radiographic axial spondyloarthritis

Simponi (golimumab) is a monoclonal antibody against tumour necrosis factor (TNF).
Simponi (golimumab) is a monoclonal antibody against tumour necrosis factor (TNF).

Further information
View Simponi drug record
Summary of Product Characteristics
Manufacturer: MSD

The licensed indications for Simponi (golimumab) have been extended to include the treatment of severe active non-radiographic axial spondyloarthritis with objective signs of inflammation in patients who are intolerant of, or unresponsive to, treatment with NSAIDs.

The recommended dose for the new indication is 50mg by sc inj monthly on the same date each month.
Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Migraine treatments and prophylactics summarised in new MIMS table

Migraine treatments and prophylactics summarised in new MIMS table

The latest quick reference table to be added to MIMS...

New research supports statin prescribing in patients over 75 years

New research supports statin prescribing in patients over 75 years

Evidence suggesting a mortality benefit of statins...